Compare IPDN & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPDN | BFRI |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | 94 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 13.2M |
| IPO Year | 2012 | N/A |
| Metric | IPDN | BFRI |
|---|---|---|
| Price | $0.78 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 73.8K | ★ 110.3K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,054,219.00 | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.68 | $0.54 |
| 52 Week High | $12.39 | $1.18 |
| Indicator | IPDN | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 58.33 |
| Support Level | N/A | $0.79 |
| Resistance Level | $1.02 | $1.17 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 28.72 | 47.06 |
Professional Diversity Network Inc provides access to networking, training, educational, and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates the majority of its revenue from the TalentAlly Network Segment.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.